Assessment of Treatment Effects By Measurable Residual Disease
   Monitoring in NPM1-Mutated AML Patients Randomized for
   Gemtuzumab-Ozogamicin (GO) within the AMLSG 09-09 Trial of the
   German-Austrian AML Study Group (AMLSG)

Kapp-Schwoerer, Silke; Weber, Daniela; Corbacioglu, Andrea; Gaidzik, Verena I.; Paschka, Peter; Kroenke, Jan; Teleanu, Maria-Veronica; Theis, Frauke; Ruecker, Frank G.; Goehring, Gudrun; Schlegelberger, Brigitte; Fiedler, Walter; Kindler, Thomas; Schroeder, Thomas Michael; Mayer, Karin; Luebbert, Michael; Wattad, Mohammed Amen; Goetze, Katharina S.; Horst, Heinz A.; Koller, Elisabeth; Wulf, Gerald; Schleicher, Jan; Bentz, Martin; Krauter, Juegen; Krzykalla, Julia; Benner, Axel; Schlenk, Richard F.; Thol, Felicitas; Heuser, Michael; Ganser, Arnold; Doehner, Hartmut; Doehner, Konstanze

doi:10.1182/blood-2018-99-114648

2018

Back
Back to start of result list
Permanent link for displayed object

Document type:: Meeting Abstract
Author(s):: Kapp-Schwoerer, Silke; Weber, Daniela; Corbacioglu, Andrea; Gaidzik, Verena I.; Paschka, Peter; Kroenke, Jan; Teleanu, Maria-Veronica; Theis, Frauke; Ruecker, Frank G.; Goehring, Gudrun; Schlegelberger, Brigitte; Fiedler, Walter; Kindler, Thomas; Schroeder, Thomas Michael; Mayer, Karin; Luebbert, Michael; Wattad, Mohammed Amen; Goetze, Katharina S.; Horst, Heinz A.; Koller, Elisabeth; Wulf, Gerald; Schleicher, Jan; Bentz, Martin; Krauter, Juegen; Krzykalla, Julia; Benner, Axel; Schlenk, Richard F.; Thol, Felicitas; Heuser, Michael; Ganser, Arnold; Doehner, Hartmut; Doehner, Konstanze «
Kapp-Schwoerer, Silke; Weber, Daniela; Corbacioglu, Andrea; Gaidzik, Verena I.; Paschka, Peter; Kroenke, Jan; Teleanu, Maria-Veronica; Theis, Frauke; Ruecker, Frank G.; Goehring, Gudrun; Schlegelberger, Brigitte; Fiedler, Walter; Kindler, Thomas; Schroeder, Thomas Michael; Mayer, Karin; Luebbert, Michael; Wattad, Mohammed Amen; Goetze, Katharina S.; Horst, Heinz A.; Koller, Elisabeth; Wulf, Gerald; Schleicher, Jan; Bentz, Martin; Krauter, Juegen; Krzykalla, Julia; Benner, Axel; Schlenk, Richard... »
Title:: Assessment of Treatment Effects By Measurable Residual Disease Monitoring in NPM1-Mutated AML Patients Randomized for Gemtuzumab-Ozogamicin (GO) within the AMLSG 09-09 Trial of the German-Austrian AML Study Group (AMLSG)
Journal title abbreviation:: Blood
Year:: 2018
Journal volume:: 132
Fulltext / DOI:: doi:10.1182/blood-2018-99-114648
Print-ISSN:: 0006-4971
TUM Institution:: III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
BibTeX

Occurrences:

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie (Prof. Bassermann)2018